Nanobiotix Announced At ESMO Saturday, Phase 1 JNJ-1900 Data Showing 41.7% Response Rate, With 4 Complete Responses, 75% Disease Control Rate, 17.8-Month Median Overall Survival In Heavily Pretreated Anti-PD-1-Resistant Advanced Melanoma

Loading news article.

Nanobiotix Announced At ESMO Saturday, Phase 1 JNJ-1900 Data Showing 41.7% Response Rate, With 4 Complete Responses, 75% Disease Control Rate, 17.8-Month Median Overall Survival In Heavily Pretreated Anti-PD-1-Resistant Advanced Melanoma | WAPE

Nanobiotix Announced At ESMO Saturday, Phase 1 JNJ-1900 Data Showing 41.7% Response Rate, With 4 Complete Responses, 75% Disease Control Rate, 17.8-Month Median Overall Survival In Heavily Pretreated Anti-PD-1-Resistant Advanced Melanoma

Article summary

Related companies

Comments —